Amgen delivered Q4 2025 revenue growth and higher GAAP profitability, reporting $9.87B in revenue, $1.33B in net income, and GAAP diluted EPS of $2.45. Non-GAAP diluted EPS was $5.29, and free cash flow was $961M for the quarter.

Amgen delivered higher revenues and net income in Q3 2025, supported by strong demand for several key products and improved free cash flow.

Amgen delivered solid Q2 2025 performance, posting growth in EPS, revenue, and net income, with 15 products achieving double-digit sales increases and robust contributions from key therapies like Repatha and EVENITY.

Amgen's Q1 2025 revenue grew to $8.1 billion with significant net income improvement due to strong product demand and an equity investment gain. Adjusted EPS rose 24%, bolstered by higher revenues and operating efficiency.

Amgen reported an 11% increase in total revenues for the fourth quarter, reaching $9.1 billion. Non-GAAP EPS increased by 13% to $5.31, driven by higher revenues, partially offset by increased operating expenses. The company's performance was bolstered by strong sales growth in several key products and strategic investments in its pipeline.

Amgen reported a strong third quarter in 2024, with total revenues increasing by 23% to $8.5 billion. Product sales grew by 24%, driven by a 29% increase in volume. GAAP EPS increased by 62% to $5.22, while non-GAAP EPS increased by 13% to $5.58. The company generated $3.3 billion in free cash flow.

Amgen reported a 20% increase in total revenues to $8.4 billion for the second quarter of 2024. Product sales also grew by 20%, driven by a 26% increase in volume. GAAP EPS decreased by 46% to $1.38, while non-GAAP EPS decreased slightly by 1% to $4.97.

Amgen reported a 22% increase in total revenues to $7.4 billion for the first quarter of 2024, driven by a 25% increase in volume and the acquisition of Horizon Therapeutics. GAAP loss per share was $0.21, while non-GAAP EPS decreased 1% to $3.96. The company generated $0.5 billion in free cash flow.

Amgen reported a 20% increase in total revenues for the fourth quarter of 2023, reaching $8.2 billion. This growth was primarily driven by a 23% increase in volume, although partially offset by a 3% decrease in net selling price. GAAP EPS decreased by 53% to $1.42, influenced by acquisition-related expenses and Horizon's operating expenses. Non-GAAP EPS increased by 15% to $4.71. The company's performance included $954 million in sales from the Horizon Therapeutics acquisition.

Amgen reported a 4% increase in total revenues to $6.9 billion, driven by an 5% increase in product sales. Volume growth of 11% included double-digit volume growth from BLINCYTO, EVENITY, Repatha and Nplate. GAAP EPS decreased 19% to $3.22, while non-GAAP EPS increased 6% to $4.96. The company generated $2.5 billion in free cash flow.

Amgen's Q2 2023 results showed a strong performance with a 6% increase in total revenues to $7.0 billion, driven by an 11% increase in product sales volume. Non-GAAP EPS increased by 8% to $5.00, and the company generated $3.8 billion in free cash flow.

Amgen reported a 2% decrease in total revenues to $6.1 billion for Q1 2023, driven by lower Other Revenue, but this was partially offset by a 2% increase in product sales due to a 14% volume growth. GAAP EPS increased by 97% to $5.28, while non-GAAP EPS decreased by 6% to $3.98. The company generated $0.7 billion in free cash flow, and is moving forward with the Horizon Therapeutics acquisition.

Amgen's Q4 2022 revenues remained largely unchanged at $6.8 billion, while GAAP EPS decreased by 11% to $3.00 and non-GAAP EPS decreased by 7% to $4.09. The company's product sales benefited from a 10% volume growth, offset by lower net selling prices and foreign exchange impacts.

Amgen's Q3 2022 financial results showed a slight decrease in total revenues, but an increase in both GAAP and non-GAAP EPS. The company's medicines generated 8% volume growth globally, with 11 products achieving record quarterly sales. The company revised its 2022 total revenues guidance to $26.0-$26.3 billion and EPS guidance to $11.46-$12.17 on a GAAP basis, and $17.25-$17.85 on a non-GAAP basis.

Amgen reported a 1% increase in total revenues to $6.6 billion for Q2 2022. GAAP EPS increased to $2.45, and non-GAAP EPS increased to $4.65. The company generated $1.7 billion in free cash flow.

Amgen reported a 6% increase in total revenues, reaching $6.2 billion, driven by volume growth in key products and contributions from COVID-19 manufacturing collaborations. GAAP EPS decreased by 5% to $2.68, while non-GAAP EPS increased by 15% to $4.25. The company reaffirmed its 2022 total revenue guidance and revised its EPS guidance.

Amgen reported a 3% increase in total revenues for Q4 2021, reaching $6.8 billion, driven by increased Other Revenue from the Eli Lilly and Company (Lilly) COVID-19 manufacturing collaboration. GAAP earnings per share (EPS) increased 22% to $3.36 in the fourth quarter driven by increased revenues and lower weighted average shares outstanding.

Amgen reported a 4% increase in total revenues to $6.7 billion for the third quarter of 2021, driven by higher unit demand. GAAP EPS decreased 3% to $3.31, while non-GAAP EPS increased 11% to $4.67. The company generated $2.2 billion in free cash flow.

Amgen reported a 5% increase in total revenues to $6.5 billion for Q2 2021, driven by higher unit demand. GAAP EPS decreased 73% to $0.81, influenced by a $1.5 billion write-off related to acquired IPR&D. Non-GAAP EPS increased 4% to $4.38, bolstered by revenue growth and fewer shares outstanding. The company reaffirmed its full-year revenue guidance and revised GAAP EPS guidance.

Amgen's first quarter 2021 results showed a decrease in total revenues by 4% to $5.9 billion, driven by lower net selling prices, though partially offset by volume growth. GAAP EPS decreased by 8% to $2.83, while non-GAAP EPS decreased by 12% to $3.70. The company reaffirmed its full-year revenue guidance and revised its GAAP EPS guidance.

Amgen's Q4 2020 financial results showed a 7% increase in total revenues to $6.6 billion, driven by volume growth. However, GAAP EPS decreased by 3% to $2.76, primarily due to Otezla acquisition costs. Non-GAAP EPS increased by 5% to $3.81. The company's 2021 revenue guidance is $25.8-$26.6 billion.

Amgen reported a 12% increase in total revenues to $6.4 billion for the third quarter of 2020, driven by higher volume growth. GAAP EPS increased by 5% to $3.43, while non-GAAP EPS increased by 19% to $4.37. The company generated $3.2 billion in free cash flow.

Amgen reported a 6% increase in total revenues to $6.2 billion for Q2 2020, driven by higher unit demand, although partially offset by lower net selling prices. GAAP EPS decreased by 15% to $3.05, primarily due to amortization costs from the Otezla acquisition, while non-GAAP EPS increased by 7% to $4.25. The company reaffirmed its 2020 total revenue guidance at $25.0-$25.6 billion and revised its EPS guidance to $10.73-$11.43 on a GAAP basis and $15.10-$15.75 on a non-GAAP basis.

Amgen reported an 11% increase in total revenues to $6.2 billion for Q1 2020 compared to Q1 2019. GAAP EPS decreased by 3% to $3.07, while non-GAAP EPS increased by 17% to $4.17. The company generated $2.0 billion in free cash flow during the quarter and reaffirmed its 2020 total revenue guidance.

Amgen reported a 1% decrease in total revenues for Q4 2019, amounting to $6.2 billion, impacted by biosimilar and generic competition. GAAP EPS decreased by 5% to $2.85, while non-GAAP EPS increased by 6% to $3.64. Product sales saw a decline, but several products including Repatha, Parsabiv, and Blincyto experienced double-digit unit growth.